Metabolic engineering study demonstrates synergistic enhancement of citric acid production in engineered Yarrowia lipolytica, highlighting potential for rare earth bioleaching applications.
Citric acid is one of the most effective organic acids for rare earth bioleaching. Yarrowia lipolytica represents a promising chassis due to its inability to produce oxalic acid; however, the metabolic bottlenecks between citrate synthesis and mitochondrial export remain to be systematically addressed. In this study, a heterologous “push–pull” strategy was applied to simultaneously reinforce citrate synthesis and mitochondrial efflux by co-overexpressing YlAMPD (encoding AMP deaminase) and AnYHM2 (encoding a mitochondrial citrate carrier from Aspergillus niger) under the strong constitutive promoters. Three recombinant strains were constructed in Yarrowia lipolytica Po1f: YlAMPD-overexpressing Po1f-pJQ08, AnYHM2-expressing Po1f-pJQ09, and the co-expression strain Po1f-pJQ12. RT-qPCR confirmed successful transcriptional activation of the target genes. Shake-flask fermentation revealed that YlAMPD and AnYHM2 single-gene overexpression strains increased citric acid production by 34.23% and 29.62%, respectively, whereas the co-expression strain achieved a titer of 22.33 g·L−1, representing a 94.51% increase over the control. This enhancement substantially exceeded the arithmetic sum of the individual increases (63.85%), thereby exhibiting a distinct supra-additive effect. This study provides a candidate strain with application potential for rare earth bioleaching and offers a referable metabolic engineering strategy for citric acid production in Yarrowia lipolytica.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: